Innate Pharma SA (IPHA) Earnings Date & Reports

Innate Pharma SA is a clinical-stage biotechnology company... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

IPHA is expected to report earnings to fall 73.33% to -7 cents per share on September 15

Innate Pharma SA IPHA Stock Earnings Reports

Q2'22

Est.

$-0.08

Q4'24

Beat

by $0.10

Q2'23

Beat

by $0.16

The last earnings report on March 27 showed earnings per share of -30 cents, beating the estimate of -40 cents. With 14.98K shares outstanding, the current market capitalization sits at 167.56M.

View a ticker or compare two or three

Compare

IPHA

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if bought

View Trends For IPHA
(Try 14 days for Free)

Ad is loading...

A.I.Advisor

published price charts

A.I. Advisor

published General Information

General Information

a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

117, Avenue de Luminy

Phone

+33 430303030

Employees

211

Web

https://www.innate-pharma.com